Side-by-side · Research reference
ARA 290vsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BFDA-ApprovedFlagship14/45 cited
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
ARA 290
Tirzepatide
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Glucose-dependent insulin release preserves physiological feedback
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
Tirzepatide
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
Indefinite for chronic indication
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Timing
Any time of day
No circadian dependence reported.
Once weekly, any time of day
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Tirzepatide
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
Tirzepatide
Injection site reaction
Mild, transient
Mild erythema, pruritus
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Pregnancy / OB
—
Contraindicated
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
ARA 290
Tirzepatide
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Pen-supplied. Research vial: 27–31G insulin syringe.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Tirzepatide
— no documented stacks